Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia DY Logunov, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, ... The Lancet 397 (10275), 671-681, 2021 | 2022 | 2021 |
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia DY Logunov, IV Dolzhikova, OV Zubkova, AI Tukhvatulin, ... The Lancet 396 (10255), 887-897, 2020 | 1253 | 2020 |
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV-and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia IV Dolzhikova, OV Zubkova, AI Tukhvatulin, AS Dzharullaeva, ... Human vaccines & immunotherapeutics 13 (3), 613-620, 2017 | 135 | 2017 |
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist LG Burdelya, CM Brackett, B Kojouharov, II Gitlin, KI Leonova, ... Proceedings of the National Academy of Sciences 110 (20), E1857-E1866, 2013 | 134 | 2013 |
Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B. 1.1. 7, B. 1.351, P. 1, B. 1.617. 2, B. 1.617. 3) and Moscow endemic SARS … VA Gushchin, IV Dolzhikova, AM Shchetinin, AS Odintsova, AE Siniavin, ... Vaccines 9 (7), 779, 2021 | 126 | 2021 |
Mycoplasma infection suppresses p53, activates NF-κB and cooperates with oncogenic Ras in rodent fibroblast transformation DY Logunov, DV Scheblyakov, OV Zubkova, MM Shmarov, ... Oncogene 27 (33), 4521-4531, 2008 | 101 | 2008 |
Toll-like receptors (TLRs): the role in tumor progression DV Shchebliakov, DY Logunov, AI Tukhvatulin, MM Shmarov, ... Acta Naturae (англоязычная версия) 2 (3 (6)), 21-29, 2010 | 97 | 2010 |
Gam-COVID-Vac Vaccine Trial Group Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised … DY Logunov, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, ... Lancet 397 (10275), 671-681, 2021 | 85 | 2021 |
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in … AI Tukhvatulin, IV Dolzhikova, DV Shcheblyakov, OV Zubkova, ... The Lancet Regional Health–Europe 11, 2021 | 65 | 2021 |
Combined stimulation of Toll-like receptor 5 and NOD1 strongly potentiates activity of NF-κB, resulting in enhanced innate immune reactions and resistance to Salmonella … AI Tukhvatulin, II Gitlin, DV Shcheblyakov, NM Artemicheva, LG Burdelya, ... Infection and immunity 81 (10), 3855-3864, 2013 | 58 | 2013 |
Non-thermal plasma causes p53-dependent apoptosis in human colon carcinoma cells AI Tuhvatulin, EV Sysolyatina, DV Scheblyakov, DY Logunov, ... Acta Naturae (англоязычная версия) 4 (3 (14)), 82-87, 2012 | 58 | 2012 |
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer A Ghochikyan, A Pichugin, A Bagaev, A Davtyan, A Hovakimyan, ... Journal of Translational Medicine 12, 1-12, 2014 | 56 | 2014 |
Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice GAL Godakova SA, Noskov AN, Vinogradova ID, Ugriumova GA, Solovyev AI ... Toxins (Basel) 11, 2019 | 53 | 2019 |
Powerful complex immunoadjuvant based on synergistic effect of combined TLR4 and NOD2 activation significantly enhances magnitude of humoral and cellular adaptive immune responses AI Tukhvatulin, AS Dzharullaeva, NM Tukhvatulina, DV Shcheblyakov, ... PLoS One 11 (5), e0155650, 2016 | 49 | 2016 |
Topical bacterial lipopolysaccharide application affects inflammatory response and promotes wound healing AV Kostarnoy, PG Gancheva, DY Logunov, LV Verkhovskaya, MA Bobrov, ... Journal of Interferon & Cytokine Research 33 (9), 514-522, 2013 | 43 | 2013 |
Virus-vectored Ebola vaccines IV Dolzhikova, EA Tokarskaya, AS Dzharullaeva, AI Tukhvatulin, ... Acta Naturae (англоязычная версия) 9 (3 (33)), 4-11, 2017 | 32 | 2017 |
Safety and efficacy of the Russian COVID-19 vaccine: more information needed–Authors’ reply DY Logunov, IV Dolzhikova, AI Tukhvatullin, DV Shcheblyakov The Lancet 396 (10256), e54-e55, 2020 | 27 | 2020 |
Retention of neutralizing response against SARS-CoV-2 omicron variant in sputnik V-Vaccinated individuals D Lapa, DM Grousova, G Matusali, S Meschi, F Colavita, A Bettini, ... Vaccines 10 (5), 817, 2022 | 26 | 2022 |
Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B. 1.1. 529 (Omicron) SARS-CoV-2 variant IV Dolzhikova, AA Iliukhina, AV Kovyrshina, AV Kuzina, VA Gushchin, ... medRxiv, 2021.12. 17.21267976, 2021 | 23 | 2021 |
Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern IA Favorskaya, DV Shcheblyakov, IB Esmagambetov, IV Dolzhikova, ... Frontiers in immunology 13, 822159, 2022 | 22 | 2022 |